Supernus Pharmaceuticals filings document regulatory disclosures for a Nasdaq-listed biopharmaceutical company focused on central nervous system diseases. Recent Form 8-K reports cover operating results, conference-call related earnings releases, material definitive agreements, executive compensation arrangements, and other material events tied to the company's CNS product portfolio and corporate obligations.
Proxy materials describe annual meeting voting matters, director elections, advisory executive compensation votes, auditor ratification, and equity incentive plan amendments. The filings also identify the company's common stock structure, exchange listing, shareholder voting mechanics, governance practices, and capital-structure disclosures.
Supernus Pharmaceuticals (SUPN) reported insider equity activity by its President, CEO and Director on 10/02/2025. The reporting person acquired 20,000 and 19,320 shares of common stock at $0 upon settlement of performance share units granted in 2021 and 2024. To cover taxes, the company withheld 7,796 and 7,529 shares at $46.21.
Following these transactions, the reporting person directly beneficially owned 1,185,228 shares. An additional 1,005,600 shares were beneficially owned indirectly via the KBT Trust. The performance share unit awards vested based on achievement of individual performance objectives set in 2021 and 2024.
Supernus Pharmaceuticals insider activity shows the company's President and CEO, Jack A. Khattar, completed option exercise and open-market sale transactions on 10/02/2025. He exercised 2,267 employee stock options at an exercise price of $25.3 per share, resulting in direct ownership of those 2,267 shares. On the same date he sold 1,904 shares in multiple trades at a weighted average price of $48.06. After these transactions the reporting person directly beneficially owned 1,161,233 shares and indirectly held 1,005,600 shares through the KBT Trust.
The exercise was made under an employee option schedule that vests in installments beginning 02/24/2018, and the sale was executed pursuant to a 10b5-1 trading plan adopted 11/14/2024. The filer offers to provide detailed breakdowns of sale prices within the reported $48.00–$48.08 range on request.
Supernus Pharmaceuticals (SUPN) filed a Form 144 reporting a proposed sale of 1,904 common shares by an insider through Morgan Stanley Smith Barney, with an aggregate market value of $91,468.16 and an approximate sale date of 10/02/2025 on NASDAQ. The filing states the shares were acquired the same day by exercise of stock options and paid in cash.
The notice also lists multiple prior 10b5-1 sales by the same account during Aug–Oct 2025, including transactions such as 40,173 shares for $1,931,063.89 on 10/01/2025 and several large sales in August and September 2025. The filer certifies no undisclosed material adverse information and references reliance on Rule 10b5-1 trading instructions where applicable.
Jack A. Khattar, President and CEO and a director of Supernus Pharmaceuticals, Inc. (SUPN), reported transactions on 10/01/2025 showing the acquisition and sale of company common stock. He acquired 53,785 shares pursuant to an employee stock option with an exercise price of $25.30 and also sold 40,173 shares at a weighted average price of $48.07. The acquisition was made under a 10b5-1 trading plan adopted November 14, 2024, and the sale occurred in multiple transactions at prices ranging from $48.00 to $48.25.
After these transactions Mr. Khattar directly beneficially owns 1,160,870 shares and indirectly (through the KBT Trust) holds 1,005,600 shares, for a combined reported interest disclosed on the form. The exercised option vests in four equal installments beginning on 02/24/2018 and expires on 02/24/2027.
Insider notice to sell 40,173 common shares of Supernus Pharmaceuticals (SUPN) is reported under Form 144. The sale is scheduled for 10/01/2025 through Morgan Stanley Smith Barney and the aggregate market value of the proposed sale is $1,919,867.67. The shares were acquired on 10/01/2025 by exercise of stock options and payment was made in cash on the same date. The filing shows 56,073,088 shares outstanding for the class referenced. The filing also lists multiple prior 10b5-1 sales by the same account over the past three months totaling 304,123 shares.
Jack A. Khattar, President, CEO and director of Supernus Pharmaceuticals (SUPN), reported transactions on 09/30/2025. He exercised an employee stock option to acquire 11,510 shares at an exercise price of $25.30 per share under a plan adopted 02/24/2018, and sold 8,588 shares in multiple trades at a weighted average price of $48.25 (individual sale prices ranged $48.00–$48.44). After these transactions Mr. Khattar beneficially owned 1,147,258 shares directly and an additional 1,005,600 shares indirectly through the KBT Trust. The option activity leaves 137,302 option shares outstanding held directly.
Form 144 filing for SUPN reports a proposed sale of 8,588 shares of common stock to be executed through Morgan Stanley Smith Barney LLC on 09/30/2025 on NASDAQ with an aggregate market value of $408,788.80. The filing states these shares were acquired and will be paid for on 09/30/2025 by exercise of stock options from the issuer. The document also lists multiple recent Rule 10b5-1 sales by Jack A. Khattar totaling numerous transactions in August and September 2025, including sales on 09/29/2025, 09/23/2025, 09/22/2025, and earlier dates, each showing amounts and gross proceeds. The filing shows total shares outstanding of 56,073,088, providing context for the size of the proposed sale within the company's capitalization.
Jack A. Khattar, President & CEO and a director of Supernus Pharmaceuticals, Inc. (SUPN), reported option-related and open-market transactions on 09/29/2025. He acquired 13,688 shares by exercising employee stock options at an exercise price of $25.30 and, on the same date, sold 10,235 shares in transactions at a weighted average price of $48.02 (sales ranged from $48.00 to $48.14). After these transactions he beneficially owns 1,144,336 shares directly and 1,005,600 shares indirectly through the KBT Trust; he also holds 148,812 option shares underlying employee stock options. The exercise was recorded as part of an option vesting schedule; the sales were made pursuant to a 10b5-1 trading plan adopted November 14, 2024. The form was signed by an attorney-in-fact on 09/30/2025.
Form 144 notice for SUPN (Supernus Pharmaceuticals, Inc.) shows an insider sale filing for common stock scheduled with Morgan Stanley Smith Barney. The filer reports proposing to sell 10,235 shares on 09/29/2025 with an aggregate market value of $481,352.05. The shares were acquired the same day (09/29/2025) via exercise of stock options and payment was in cash. The filing lists total shares outstanding of 56,073,088, which places the proposed sale at a very small fraction of outstanding stock. The notice also discloses multiple Rule 10b5-1 sales by Jack A. Khattar during August–September 2025 totaling 285,300 shares for combined gross proceeds of approximately $12,588,665.79. The filer certifies no undisclosed material adverse information and references Rule 10b5-1 plan representations.
Jonathan Rubin, SVP and Chief Medical Officer of Supernus Pharmaceuticals (SUPN), reported transactions on 09/25/2025 relating to Performance Share Units (PSUs). 1,875 shares of common stock were acquired on settlement of PSUs at $0 (transaction code M) and 840 shares were withheld to satisfy tax withholding at a price of $46.21 (transaction code F).
Following these transactions, Mr. Rubin beneficially owned 11,015 shares (direct ownership). The filing notes the PSUs were granted on February 22, 2024, with certain awards vesting upon achievement of individual performance objectives established June 24, 2024.